Advertisement intended for health care professionals

l

BPDCN

Author: James Leveson; Adrian Choy; Sabine Pomplun; Ke Xu, MD, 09/19/2026
Category: Myeloid Neoplasms and acute leukemia (WHO 2016) > Blastic plasmacytoid dendritic cell neoplasm
Published Date: 11/10/2026

An 80-year-old male presented with anemia, thrombocytopenia, monocytosis and skin lesions. Hb 104 g/L, WBC 14, lymphocytes 2.38 x 109/L, neutrophil 9.36 x 109/L, monocytes 2.21 x 109/L, platelet 24 x 109/L.

Bone marrow aspirate showed 50% large blastoid cells with open chromatin, nucleoli and cytoplasmic vacuolation. Flow cytometry showed these cells were positive for HLADR, CD38, CD33wk, CD4wk, CD16wk, and CD1a(wk), and negative for CD34, CD117, cCD3, and cMPO. Myeloid NGS detected concurrent ETV6 p.Asn172Ter (VAF 62%), SRSF2 p.pro95Leu (VAF 36%), TET2 p.Val218TrpfsTer32 (VAF 47%) and TET2 p.Arg1400GlufsTer48 (VAF 49%) variants. No fusions were detected. FISH and SNP array studies demonstrated a complex genome with monosomy of chromosomes 9 and 13 and ETV6 gene loss. The trephine sample was effaced by large cells with indented nuclei and open chromatin. They were positive for CD4 and CD123, but negative for CD34, CD117, MPO and CD56. Tumour cells were E-cadherin positive with a moderate proliferation rate (Ki-67 ~30%). Skin biopsy showed BPDCN cells. They were positive for CD123, CD4 and CD56.

The patient was diagnosed with BPDCN and was treated with venetoclax and azacitidine.

Advertisement intended for health care professionals